Neuromuscular

Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.

The agent’s developer, Argenx, stated that it plans on submitting a biologics license application (BLA) to the FDA by the end of 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.

The consultant for the Muscular Dystrophy Association’s Chief Medical Advisory Team and associate professor of neurology at Columbia University offered his perspective on some of the latest news in ALS.

The newly appointed director for the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital details his personal responsibilities and the long-term goals for the new center.

The staff neurologist, Vice-Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute detailed his experience managing patients with various conditions through a telemedicine platform.

Neurology News Network for the week ending May 23, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

Cure SMA joins the list of influential and impactful organizations within the Strategic Alliance Program.

The staff neurologist, Vice-Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute discussed the institute’s transition to telemedicine and how it has been utilized.

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.

The newly appointed director for the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital gives an overview on what neurologic disorders the new center will focus on.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

Finkel discussed his new role at St. Jude Children’s Research Hospital, where he'll head up the new Center for Experimental Neurotherapeutics.

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

Neurology News Network for the week ending May 9, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 8, 2020.

Data showed that Ovid Therapeutics’ gaboxadol, also known as OV101, was well-tolerated and had a significant effect on secondary behavioral end points in the 3 combined study groups.

Early treatment with Ionis Pharmaceuticals’s inotersen resulted in greater long-term disease stabilization than delayed initiation.

This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.

The assistant professor of neurology at the University of Washington in St. Louis discussed the need for a systemic, multi-specialist approach to cerebral palsy and provided the main takeaways from her and her colleagues’ work.

Neurology News Network for the week ending May 2.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 1, 2020.

The assistant professor of neurology at the University of Washington in St. Louis detailed the ­­factors that may contribute to these inconsistencies in cerebral palsy diagnosis and what role neurologists should play.